Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Wild

Showing results (151-160 of 153) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 153 results.
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing|March 3, 2004
The status of structural genomics defined through the analysis of current targets and structuresP E Bourne, C K J Allerston, W Krebs, et al.
Molecular Pain|December 1, 2016
Selective antagonism of TRPA1 produces limited efficacy in models of inflammatory- and neuropathic-induced mechanical hypersensitivity in ratsSonya G Lehto, Andy D Weyer, Beth D Youngblood, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 24, 2004
AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic propertiesNarender R Gavva, Rami Tamir, Yusheng Qu, et al.
Pageof 16

Showing results (151-160 of 153) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 153 results.
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing|March 3, 2004
The status of structural genomics defined through the analysis of current targets and structuresP E Bourne, C K J Allerston, W Krebs, et al.
Molecular Pain|December 1, 2016
Selective antagonism of TRPA1 produces limited efficacy in models of inflammatory- and neuropathic-induced mechanical hypersensitivity in ratsSonya G Lehto, Andy D Weyer, Beth D Youngblood, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 24, 2004
AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic propertiesNarender R Gavva, Rami Tamir, Yusheng Qu, et al.
Pageof 16